Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
Landos Biopharma (NASDAQ: LABP) announced that its Chairman and CEO, Josep Bassaganya-Riera, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:00 AM EDT. The presentation will showcase Landos' innovative LANCE A.I. platform, which is designed to develop novel oral therapeutics for autoimmune diseases. The live webcast can be accessed on the company's website, where it will also be archived after the event.
Landos is advancing 17 development programs targeting novel immunometabolic pathways, including treatments for ulcerative colitis and Crohn's disease.
- None.
- None.
BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:00 AM EDT.
A live webcast of the presentation will be accessible through the Investors/Media section of the Company’s website at www.landosbiopharma.com. Following the event, the webcast will be archived on the Landos website.
About Landos Biopharma
Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. For more information, please visit www.landosbiopharma.com.
Contacts:
Michael K. Levitan (investors)
Solebury Trout
646-378-2920
mlevitan@soleburytrout.com
Hannah Gendel (media)
Solebury Trout
646-378-2943
hgendel@soleburytrout.com
FAQ
What is the date and time of Landos Biopharma's presentation at the Jefferies Virtual Healthcare Conference?
Who will be presenting for Landos Biopharma at the Jefferies Virtual Healthcare Conference?
How can I access the webcast of Landos Biopharma's presentation?
What innovative platform does Landos Biopharma use for drug development?
What diseases does Landos Biopharma focus on treating?
